News
Investor's Business Daily on MSN55m
Novo Nordisk Rallied On Wegovy's Newest Approval. But This Rival Rallied More.
Novo Nordisk stock jumped Monday after the FDA approved the company's obesity drug, Wegovy, as a treatment for MASH.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback